Sequential immunosuppression: three years' experience in 240 cadaveric renal transplants.
Light
J A
JA
Transplantation Services, Washington Hospital Center, Washington, DC 20010.
Jonsson
J
J
Khawand
N
N
Ali
A
A
Aquino
A
A
Currier
C B
CB
Romolo
J
J
Gonzalez
J
J
Korb
S
S
D000911:Antibodies, Monoclonal / Q000008:administration & dosage; D000961:Antilymphocyte Serum / Q000627:therapeutic use; D002102:Cadaver; D003141:Communicable Diseases / Q000150:complications; D004306:Dose-Response Relationship, Immunologic; D006084:Graft Rejection; D006085:Graft Survival; D006801:Humans; D007165:Immunosuppression Therapy / Q000379:methods*; D016030:Kidney Transplantation / Q000379:methods*; D016853:Muromonab-CD3; D016019:Survival Analysis
D000911:Antibodies, Monoclonal; D000961:Antilymphocyte Serum; D016853:Muromonab-CD3